Search Result

Results for "

novo

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (2) Antibiotic (2) Antifolate (4) Apoptosis (10) Arenavirus (1) ATP Synthase (2) Bacterial (2) Bcl-2 Family (4) Caspase (4) Cytochrome P450 (1) Dihydroorotate Dehydrogenase (1) DNA Methyltransferase (2) DNA-PK (1) DNA/RNA Synthesis (16) Drug Metabolite (3) Endogenous Metabolite (27) Fatty Acid Synthase (FASN) (2) Fungal (1) HBV (1) HCV (4) IFNAR (1) Interleukin Related (1) Isotope-Labeled Compounds (13) JAK (2) NO Synthase (1) Nucleoside Antimetabolite/Analog (8) Phosphoglycerate Dehydrogenase (PHGDH) (3) PKC (1) SARS-CoV (1)
By Research Areas:	Cancer (34) Endocrinology (1) Infection (23) Inflammation/Immunology (6) Metabolic Disease (12)
Oligonucleotides:	Nucleotides and their Analogs (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Lometrexol 1 Publications Verification DDATHF	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF), an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol has anticancer activity. Lometrexol also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor .

Lometrexol hydrate 1 Publications Verification DDATHF hydrate	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF) hydrate, an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol hydrate can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol hydrate has anticancer activity. Lometrexol hydrate also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor .

Lometrexol disodium 1 Publications Verification DDATHF disodium	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF) disodium, an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol disodium can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol disodium has anticancer activity. Lometrexol disodium also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor .

6-Thio-2'-Deoxyguanosine 6-thio-dG; β-TGdR	DNA/RNA Synthesis	Cancer
6-Thio-2'-Deoxyguanosine is a nucleoside analogue that can be incorporated into de novo-synthesized telomeres by telomerase.

Oleamide 1 Publications Verification	Endogenous Metabolite	Others
Oleamide is an endogenous fatty acid amide which can be synthesized de novo in the mammalian nervous system, and has been detected in human plasma.

5-Methyl-2'-deoxycytidine 1 Publications Verification 5-Methyldeoxycytidine	DNA Methyltransferase Endogenous Metabolite	Others
5-Methyl-2'-deoxycytidine in single-stranded DNA can act in cis to signal de novo DNA methylation .

Fumonisin B2	Acyltransferase	Infection
Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis .

Rhizopterin Formylpteroic acid	Others	Endocrinology
Rhizopterin is a growth factor that can form rhizobactin de novo in synthetic medium lacking folate .

Pimeloyl-CoA	Others	Metabolic Disease
Pimeloyl-CoA is a biotin precursor of Escherichia coli. Pimeloyl-CoA can be used for the research of the pathway of de novo biotin biosynthesis in Escherichia coli .

Pimeloyl-CoA lithium	Others	Metabolic Disease
Pimeloyl-CoA lithium is a biotin precursor of Escherichia coli. Pimeloyl-CoA lithium can be used for the research of the pathway of de novo biotin biosynthesis in Escherichia coli .

Carboxyaminoimidazole ribotide CAIR; 4-Carboxy-AIR	Endogenous Metabolite	Infection
Carboxyaminoimidazole ribotide (CAIR) is a metabolite of E. coli. Carboxyaminoimidazole ribotide can be used to detect distinctive features of E. coli PurE active site and synthesis fungal de novo purine .

CJ28	Endogenous Metabolite	Cancer
CJ28 is a cortisol biosynthesis inhibitor that significantly inhibits basal and stimulated cortisol production in human adrenal carcinoma cell lines. CJ28 exhibits inhibitory effects by reducing steroidogenesis and de novo cholesterol biosynthesis .

5-DACTHF 543U76; 5,11-Methenyltetrahydrohomofolate	Others	Cancer
5-DACTHF (543U76) is an inhibitor of purine de novo biosynthesis. 5-DACTHF is a GAR-TFase and AICAR-TFase inhibitor (IC₅₀: 3 and 94 μM). 5-DACTHF is a potent antitumor agent .

Fumonisin B1 5 Publications Verification	Acyltransferase	Infection
Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .

Triciribine phosphate sodium TCN-P sodium	ATP Synthase	Metabolic Disease
Triciribine phosphate sodium inhibits amidophosphoribosyltransferase by an allosteric mechanism which affects the first committed step of de novo purine biosynthesis. Triciribine phosphate sodium also inhibits IMP dehydrogenase which is the first committed step of guanosine nucleotide synthesis. Tricilibine phosphate does not affect ligase activity .

BMS-566419	Others	Others
BMS-566419 is an acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase (IMPDH). Inosine monophosphate dehydrogenase (IMPDH) is a key enzyme in the de novo synthesis of guanosine nucleotides. BMS-566419 has clinical utility for the research of transplant rejection .

N-Formyldemecolcine	Others	Others
N-Formyldemecolcine is a colchicine precursor that contains the characteristic tropolone ring and pharmacophore of colchicine. N-Formyldemecolcine can be synthesized de novo by genetically engineering transgenic Nicotiana benthamiana and atypical cytochrome P450s that catalyze the production of colchicine's unique carbon scaffold .

SAICAR 1 Publications Verification	Endogenous Metabolite	Cancer
SAICAR is an intermediate of de novo purine nucleotide biosynthesis, activates pyruvate kinase isoform M2 (PKM2) in an isozyme-selective manner, with an EC₅₀ of 0.3 mM. SAICAR stimulates PKM2 and promotes cancer cell survival in glucose-limited conditions .

Triciribine phosphate TCN-P	ATP Synthase	Metabolic Disease
Triciribine phosphate (TCN-P) inhibits amidophosphoribosyltransferase by an allosteric mechanism which affects the first committed step of de novo purine biosynthesis. Triciribine phosphate also inhibits IMP dehydrogenase which is the first committed step of guanosine nucleotide synthesis. Tricilibine phosphate does not affect ligase activity .

GDP-L-fucose disodium	Endogenous Metabolite	Metabolic Disease
GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway .

Mycophenolate Mofetil 5+ Cited Publications RS 61443; TM-MMF	Drug Metabolite Apoptosis Endogenous Metabolite Bacterial	Cancer
Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation .

LY243246 (6S)-DDATHF	Antifolate	Cancer
LY243246 ((6S)-DDATHF), the 6S diastereomer of DDATHF, is a potent competitive inhibitor of 5’-phosphoribosylglycinamide formyltransferase (GAR transformylase). 6R- and 6S-diastereomers of DDATHF are remarkably similar and equiactive antimetabolites inhibitory to de novo purine synthesis .

2,4-Diamino-6-hydroxypyrimidine 1 Publications Verification	NO Synthase	Inflammation/Immunology
2,4-Diamino-6-hydroxypyrimidine is a specific GTP cyclohydrolase I inhibitor (the rate-limiting enzyme in de novo pterin synthesis). 2,4-Diamino-6-hydroxypyrimidine blocks Tetrahydrobiopterin (BH4) synthesis and suppresses NO production .

ML-60218 4 Publications Verification	DNA/RNA Synthesis	Infection Cancer
ML-60218 is a broad-spectrum RNA pol III inhibitor, with IC₅₀s of 32 and 27 μM for Saccharomyces cerevisiae and human. ML-60218 disrupts already assembled viroplasms and to hamper the formation of new ones without the need for de novo transcription of cellular RNAs .

Sparfosic acid	Apoptosis	Metabolic Disease Cancer
Sparfosic acid, a DNA antimetabolite agent, is a potent inhibitor of aspartate transcarbamoyl transferase, the enzyme catalyzing the second step of de novo pyrimidine biosynthesis. Sparfosic acid synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines .

hDHODH-IN-12	DNA/RNA Synthesis Dihydroorotate Dehydrogenase	Cancer
hDHODH-IN-12 is a potent DHODH inhibitor with an IC₅₀ value of 0.421 μM. DHODH is the rate-limiting enzyme in the de novo synthesis of pyrimidine which is essential in DNA/RNA Synthesis. hDHODH-IN-12 is present in the inner membrane of human mitochondria.hDHODH-IN-12 can be used for the research of lung cancer .

Vebicorvir 1 Publications Verification ABI-H0731	HBV	Infection Inflammation/Immunology
Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC₅₀s from 1.84 μM to 7.3 μM .

2-Deoxy-2-fluoro-L-fucose	Others	Cancer
2-Deoxy-2-fluoro-L-fucose, an L-fucose analog, is a fucosylation inhibitor. 2-Deoxy-2-fluoro-L-fucose inhibits de novo synthesis of GDP-fucose in mammalian cells. Fucosylation is a relatively well-defined biomarker for progression in many human cancers; for example, pancreatic and hepatocellular carcinoma .

ML356	Others	Cancer
ML356 (Compound 16) is an inhibitor for fatty acid synthase (FAS), that inhibits the thioesterase domain of FAS (FAS TE) with an IC₅₀ of 0.334 μM, and blocks the de novo palmitate synthesis in PC-3 cell with an IC₅₀ of 20 μM. ML356 exhibits good membrane permeability, and good stability in human and mouse plasma .

PKUMDL-WQ-2101	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PKUMDL-WQ-2101 is a non-NAD ⁺-competing allosteric phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC₅₀ of 34.8 μM. PKUMDL-WQ-2101 exhibits antitumor activity .

Sparfosic acid trisodium 2 Publications Verification	Apoptosis	Metabolic Disease Cancer
Sparfosic acid trisodium is a DNA antimetabolite agent and a potent inhibitor of aspartate transcarbamoyl transferase. Aspartate transcarbamoyl transferase catalyzes the second step of de novo pyrimidine biosynthesis. Sparfosic acid trisodium synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines .

Cytidine-5'-triphosphate disodium hydrate Cytidine triphosphate disodium hydrate; 5'-CTP disodium hydrate	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Endogenous Metabolite	Infection Cancer
Cytidine 5′-triphosphate is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule?in the de novo?pyrimidine biosynthetic pathway in?T. gondii .

CBR-5884 Maximum Cited Publications 17 Publications Verification	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
CBR-5884 is an active, selective inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC₅₀ of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity. CBR-5884 selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis .

Mycophenolate Mofetil-d4	Isotope-Labeled Compounds Drug Metabolite Apoptosis Endogenous Metabolite	Cancer
Mycophenolate Mofetil-d₄ is the deuterium labeled Mycophenolate Mofetil. Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation[1].

Setrobuvir ANA598	DNA/RNA Synthesis HCV SARS-CoV	Infection
Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC₅₀s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition .

L-Alanosine 1 Publications Verification NSC-153353; SDX-102	Antibiotic	Infection Cancer
L-Alanosine (NSC-153353), an antibiotic from Streptomyces alanosinicus, has antineoplastic activity. L-Alanosine (NSC-153353) inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate. L-Alanosine (NSC-153353) blocks the common de novo purine biosynthesis pathway and, thereby, inhibits tumor cells with MTAP deficiency .

Lomibuvir 2 Publications Verification VX-222	DNA/RNA Synthesis HCV	Infection
Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a K_d of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC₅₀ of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .

Mycophenolate Mofetil (Standard) RS 61443 (Standard); TM-MMF (Standard)	Drug Metabolite Apoptosis Endogenous Metabolite Bacterial	Cancer
Mycophenolate Mofetil (Standard) is the analytical standard of Mycophenolate Mofetil. This product is intended for research and analytical applications. Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation .

Cytidine-5'-triphosphate 2 Publications Verification Cytidine triphosphate; 5'-CTP	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Endogenous Metabolite	Infection Cancer
Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii .

COQ7-IN-1	Others	Metabolic Disease
COQ7-IN-1, a highly potent inhibitor of human coenzyme Q (COQ7), interferes with ubiquinone (UQ) synthesis. COQ7-IN-1 does not disturb physiological cell growth of human normal culture cells. COQ7-IN-1 can be used for the research of the balance between UQ supplementation pathways: de novo UQ synthesis and extracellular UQ uptake .

Orotidine 5′-monophosphate trisodium Orotidine monophosphate trisodium; Orotidylic acid trisodium	Endogenous Metabolite DNA/RNA Synthesis	Metabolic Disease
Orotidine 5'-monophosphate trisodium is a pyrimidine nucleotide. Orotidine 5'-monophosphate trisodium is synthesized via the de novo synthesis pathway for DNA synthesis in a large number of microorganisms including M. tuberculosis, S. cerevisiae, S. typhimurium and P. falciparum to name a few. The synthesis of orotidine 5'-monophosphate trisodium uses phosphoribosyl pyrophosphate (PRPP) and orotic acid (OA) as the substrates catalyzed by orotate phosphoribosyltransferase (OPRT) .

Cat. No.	Product Name

HY-L0087V

Life Chemicals HTS Compound Collection	503,810 compounds
Life Chemicals Collection of small organic molecules for high-throughput screening currently contains 503,810 off-the-shelf products. The Collection is being permanently replenished with de novo designed products having optimal physicochemical parameters for drug discovery.

HY-L182

Fatty Acids Compound Library

296 compounds

Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases.

MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Cat. No.	Product Name	Type

HY-134433A

GDP-L-fucose disodium	Carbohydrates
GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway .

Cat. No.	Product Name	Target	Research Area

HY-P10329

KK14(R)	Fungal	Infection
KK14(R) is an analog of the de novo synthetic peptide KK14, which exhibits antifungal activity against Fusarium culmorum, Penicillium expansum and Aspergillus niger , with MICs of 6.25, 12.5 and 12.5 μg/mL, respecitvely. KK14(R) exhibits good heat- and pH-stability. KK14(R) exhibits cytotoxicity against cells Caco-2 and RAW264.7 .

Cat. No.	Product Name	Chemical Structure

HY-B0199S

Mycophenolate Mofetil-d4

Mycophenolate Mofetil-d₄ is the deuterium labeled Mycophenolate Mofetil. Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation[1].

HY-101981S

Uridine 5'-monophosphate-15N2
Uridine 5'-monophosphate-15N2 is the 15N labeled Uridine 5'-monophosphate[1]. Uridine 5'-monophosphate (5'- Uridylic acid), a monophosphate form of UTP, can be acquired either from a de novo pathway or degradation products of nucleotides and nucleic acids in vivo and is a major nucleotide analogue in mammalian milk[2].

HY-19939S

VX-984 4 Publications Verification
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .

HY-126585S

SAICAR-d1
SAICAR-d is the deuterium labeled SAICAR. SAICAR is an intermediate of de novo purine nucleotide biosynthesis, activates pyruvate kinase isoform M2 (PKM2) in an isozyme-selective manner, with an EC50 of 0.3 mM. SAICAR stimulates PKM2 and promotes cancer cell survival in glucose-limited conditions[1][2].

HY-N6723S

Fumonisin B2-13C34
Fumonisin B2- ¹³C₃₄ is the ¹³C labeled Fumonisin B2 (HY-N6723) . Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis .

HY-N6719S

Fumonisin B1-13C34
Fumonisin B1- ¹³C₃₄ is the ¹³C labeled Fumonisin B1 (HY-N6719) . Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .

HY-101981S4

Uridine 5'-monophosphate-13C9 dilithium
Uridine 5'-monophosphate- ¹³C₉ (5'-?Uridylic acid- ¹³C₉) dilithium is ¹³C-labeled Uridine 5'-monophosphate (HY-101981). Uridine 5'-monophosphate (5'-?Uridylic acid), a monophosphate form of UTP, can be acquired either from a de novo pathway or degradation products of nucleotides and nucleic acids in vivo and is a major nucleotide analogue in mammalian milk.

HY-101981S5

Uridine 5'-monophosphate-15N2 dilithium
Uridine 5'-monophosphate- ¹⁵N₂ (5'-?Uridylic acid- ¹⁵N₂) dilithium is ¹⁵N labeled Uridine 5'-monophosphate (HY-101981). Uridine 5'-monophosphate (5'-?Uridylic acid), a monophosphate form of UTP, can be acquired either from a de novo pathway or degradation products of nucleotides and nucleic acids in vivo and is a major nucleotide analogue in mammalian milk.

HY-101981S2

Uridine 5'-monophosphate-d11 dilithium
Uridine 5'-monophosphate-d₁₁ (5'-?Uridylic acid-d₁₁) dilithium is deuterium labeled Uridine 5'-monophosphate (HY-101981). Uridine 5'-monophosphate (5'-?Uridylic acid), a monophosphate form of UTP, can be acquired either from a de novo pathway or degradation products of nucleotides and nucleic acids in vivo and is a major nucleotide analogue in mammalian milk.

HY-101981S3

Uridine 5'-monophosphate-13C9,15N2 dilithium

Uridine 5'-monophosphate- ¹³C₉, ¹⁵N₂ (5'-?Uridylic acid- ¹³C₉, ¹⁵N₂) dilithium is ¹³C and ¹⁵N-labeled Uridine 5'-monophosphate (HY-101981). Uridine 5'-monophosphate (5'-?Uridylic acid), a monophosphate form of UTP, can be acquired either from a de novo pathway or degradation products of nucleotides and nucleic acids in vivo and is a major nucleotide analogue in mammalian milk.

HY-117287

Deucravacitinib

15+ Cited Publications

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .

HY-101981S1

Uridine 5'-monophosphate-15N2,d11 dilithium

Uridine 5'-monophosphate- ¹⁵N₂,d₁₁ (5'-?Uridylic acid- ¹⁵N₂,d₁₁) dilithium is deuterium and ¹⁵N labeled Uridine 5'-monophosphate (HY-101981). Uridine 5'-monophosphate (5'-?Uridylic acid), a monophosphate form of UTP, can be acquired either from a de novo pathway or degradation products of nucleotides and nucleic acids in vivo and is a major nucleotide analogue in mammalian milk.

HY-125818S1

Cytidine-5′-triphosphate-d14 disodium

Cytidine-5′-triphosphate-d14 (disodium) is the deuterium labeled Cytidine-5'-triphosphate[1]. Cytidine 5′-triphosphate (Cytidine triphosphate;5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii[2].

HY-131968

BMS-986202

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-125818S3

Cytidine-5'-triphosphate-13C9 dilithium

Cytidine-5'-triphosphate- ¹³C₉ (Cytidine triphosphate- ¹³C₉ dilithium; 5'-CTP- ¹³C₉) dilithium is ¹³C-labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule?in the de novo?pyrimidine biosynthetic pathway in?T. gondii.

HY-125818S6

Cytidine-5'-triphosphate-15N3 dilithium

Cytidine-5'-triphosphate- ¹⁵N₃ (Cytidine triphosphate- ¹⁵N₃ dilithium; 5'-CTP- ¹⁵N₃) dilithium is ¹⁵N labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule?in the de novo?pyrimidine biosynthetic pathway in?T. gondii.

HY-125818S4

Cytidine-5'-triphosphate-d14 dilithium

Cytidine-5'-triphosphate-d₁₄ (Cytidine triphosphate-d₁₄ dilithium; 5'-CTP-d₁₄) dilithium is deuterium labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule?in the de novo?pyrimidine biosynthetic pathway in?T. gondii.

HY-125818S2

Cytidine-5'-triphosphate-13C,d1 dilithium

Cytidine-5'-triphosphate- ¹³C,d₁ (Cytidine triphosphate- ¹³C,d₁ dilithium; 5'-CTP- ¹³C,d₁) dilithium is deuterium and ¹³C-labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule?in the de novo?pyrimidine biosynthetic pathway in?T. gondii.

HY-125818S5

Cytidine-5'-triphosphate-15N3,d14 dilithium

Cytidine-5'-triphosphate- ¹⁵N₃,d₁₄ (Cytidine triphosphate- ¹⁵N₃,d₁₄ dilithium; 5'-CTP- ¹⁵N₃,d₁₄) dilithium is deuterium and ¹⁵N labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule?in the de novo?pyrimidine biosynthetic pathway in?T. gondii.

Cat. No.	Product Name		Classification

HY-125818

Cytidine-5'-triphosphate 2 Publications Verification Cytidine triphosphate; 5'-CTP		Nucleotides and their Analogs
Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks